- Investing Ideas
- /
- Hong Kong Pharmaceuticals & Biotech Undervalued based on future growth
Hong Kong Pharmaceuticals & Biotech Undervalued based on future growth
Results
4
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
4 companies
China Shineway Pharmaceutical Group
Market Cap: HK$6.2b
An investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People’s Republic of China and Hong Kong.
2877
HK$8.22
7D
-3.5%
1Y
4.7%
Viva Biotech Holdings
Market Cap: HK$3.5b
An investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide.
1873
HK$1.67
7D
-4.6%
1Y
221.2%
Essex Bio-Technology
Market Cap: HK$2.9b
An investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally.
1061
HK$5.11
7D
-7.4%
1Y
117.4%
JBM (Healthcare)
Market Cap: HK$2.4b
An investment holding company, engages in the manufacture, marketing, distribution, and sale of branded healthcare and wellness products in Hong Kong, Macau, Mainland China, and internationally.
2161
HK$2.97
7D
-2.3%
1Y
203.1%